Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diabetes drug
Biotech
Roche’s GLP-1/GIP diabetes data fuel best-in-disease hopes
The phase 2 trial hit its primary endpoints, painting the asset as a potential treatment for people with type 2 diabetes and overweight or obesity.
Nick Paul Taylor
Sep 22, 2026 5:20am
Sparrow flits forward with $95M for midstage diabetes asset
Sep 24, 2025 11:22am
FDA lifts diabetes hold after Biomea mitigates liver tox risk
Sep 27, 2024 7:10am
Novo Nordisk axes once-monthly GLP-1/GIP agonist MASH prospect
Aug 7, 2024 7:00am
Diabetes biotech stock tanks as FDA imposes full clinical hold
Jun 7, 2024 8:13am
A 'live fire exercise' with COVID preps SAB for new (old) focus
Oct 16, 2023 6:00am
